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KIR2DL4 is an unusual killer cell immunoglobulin-like receptor (KIR) familymember in terms
of its structure, expression, cellular localization, and signaling properties. The most con-
served KIR in evolution, it is referred to as a framework KIR gene and is expressed by all
natural killer (NK) cells and a subset ofT cells. Although it has a long cytoplasmic tail that is
typical of inhibitory KIR, engagement of this receptor results in the activation of NK cells,
not for cytotoxicity, but for cytokine and chemokine secretion. Unlike all other KIRs, which
are expressed on the surface of NK cells, KIR2DL4 resides in endosomes. It signals from
this intracellular site for a proinﬂammatory and proangiogenic response, using a novel endo-
somal signaling pathway that involves the serine/threonine kinases DNA-PKcs and Akt.The
only known ligand of KIR2DL4 is HLA-G. Soluble HLA-G accumulates in KIR2DL4+ endo-
somes. Unlike classical HLAmolecules that serve as ligands for other KIR family members,
in healthy individuals, HLA-G expression is restricted to the fetal trophoblast cells that
invade the maternal decidua during early pregnancy. Since NK cells constitute the pre-
dominant lymphocyte subset at this site, the proinﬂammatory/proangiogenic outcome of
the interaction between KIR2DL4 and soluble HLA-G supports a role for KIR2DL4 in the
extensive remodeling of the maternal vasculature during the early weeks of pregnancy.
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INTRODUCTION
The killer cell immunoglobulin-like receptor (KIR) family of acti-
vating and inhibitory receptors expressed by natural killer (NK)
cells regulates their responsiveness to signals received from their
environment. NK cells respond to contact with other cells includ-
ing tumor cells or virus-infected cells, and to soluble mediators
such as cytokines, chemokines, or other soluble ligands. KIR reg-
ulate the activation state of NK cells upon recognition of their
major histocompatibility complex (MHC) ligands on the surface
of target cells (Long, 2008). There is genetic evidence that com-
binations of KIR and MHC genes contribute directly to different
aspects of immunity, such as resistance to infections, susceptibility
to autoimmune diseases, transplantation outcomes, and disorders
of pregnancy (Parham, 2005).
KIR2DL4 (CD158d), the anchor gene in the middle of the KIR
complex, is characterized by its low polymorphism, high degree of
conservation among primates, and by its central location among
the highly variable KIR family members. There are KIR2DL4 alle-
les with either 9 or 10 consecutive adenines in exon 6, which
encodes the transmembrane domain. This 9A/10A transmem-
brane genetic polymorphism can result in a truncated receptor
encoded by 9A, the function of which is unclear (Goodridge
et al., 2003). Unlike other KIR genes that display variegated
expression among individual NK cells, KIR2DL4 is constitutively
expressed by all NK cells and on all KIR haplotypes (Rajagopalan
and Long, 1999).
KIR2DL4 is unusual inmany other respects, including its struc-
ture, localization, and signaling function (Figure 1). Unlike KIR
with two Ig domains (KIR2DL, KIR2DS) that have a D1 and
D2 domain structure, and KIR with three Ig domains (KIR3DL,
KIR3DS) with D0, D1, and D2 domains, KIR2DL4 has a hybrid
D0–D2 domain structure. Despite having a long cytoplasmic tail
characteristic of inhibitory KIR, it carries only a single immunore-
ceptor tyrosine-based inhibitory motif (ITIM) and displays very
weak inhibitory potential (Faure and Long, 2002). Similar to
the activating KIR (KIR2DS, KIR3DS) that associate with the
immunoreceptor tyrosine-based activatingmotif (ITAM)contain-
ing adaptor DAP12 through a charged amino acid (lysine) in their
transmembrane domain, KIR2DL4 has another charged amino
acid (arginine) near the top of its transmembrane region. This
arginine endows KIR2DL4 with the ability to pair with the γ chain
of FcεR1 and to signal for cytotoxicity and cytokine secretionwhen
engaged at the cell surface (Kikuchi-Maki et al., 2005).
ENDOSOMAL LOCALIZATION
Unlike otherKIRs that are present on theNKcell surface,KIR2DL4
is undetectable at the surface of primary resting NK cells isolated
fromperipheral blood (Goodridge et al., 2003; Kikuchi-Maki et al.,
2003; Rajagopalan et al., 2006). Yet, in primary NK cells, engage-
ment of the receptor using soluble agonist antibodies activates
robust cytokine secretion but no cytotoxicity (Rajagopalan et al.,
2006). This is due to the constitutive localization of the receptor in
endosomes, where it resides. However, surface levels can be tran-
siently up-regulated upon culture of these NK cells in interleukin
2 (IL-2; Kikuchi-Maki et al., 2003; Rajagopalan et al., 2006). Weak
cytotoxicity upon KIR2DL4 engagement at the cell surface has
been detected in IL-2 dependent NK cell lines and IL-2 activated
NK cell cultures activated with IL-2 in which a low level of cell
surface KIR2DL4 can be detected by ﬂow cytometry (Goodridge
et al., 2003; Kikuchi-Maki et al., 2003). In such cells, there is the
potential to signal via the adaptor FcεRIγ for cytotoxic responses
(Kikuchi-Maki et al., 2005). However, resting NK cells with no
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FIGURE 1 | Overview of the KIR family of inhibitory (red) and activating
(green) NK cell receptors.They bind MHC-I molecules and are located on the
cell surface, with the exception of KIR2DL4, which is present in endosomes.
The activating receptors interact with the adapters DAP12 or FcRγ via
charge-based interactions in the transmembrane region. The KIR2DL/3DL
receptors (except KIR2DL4) use ITIM-based inhibitory signaling pathways
to block NK effector functions, while KIR2DS/3DS receptors activate NK
cells via ITAM-based pathways. In contrast, KIR2DL4 signals from
endosomes for a unique secretory response, but does not activate
cytotoxicity.
apparent surface expression of KIR2DL4 lack the potential to trig-
ger killing, while being fully competent to induce strong cytokine
responses (Rajagopalan et al., 2001). Thus, it is important to note
that lack of surface KIR2DL4 does not imply lack of receptor
expression or the absence of activating function.
In spite of negligible levels of KIR2DL4 on the surface of
primary, unstimulated NK cells, activation via soluble antibod-
ies resulted in robust interferon gamma (IFN-γ) secretion in
the absence of cytotoxicity (Rajagopalan et al., 2006). This is
explained by the ﬁnding that at steady state, the majority of
KIR2DL4 is intracellular. In cells treated with the K44A domi-
nant negative mutant of dynamin, a GTPase with a central role
in clathrin-mediated endocytosis, there was a striking redistri-
bution of the receptor to the plasma membrane, suggesting that
KIR2DL4 reaches endosomes by endocytosis (Rajagopalan et al.,
2006). KIR2DL4 is localized selectively in early endosomes that
are associated with Rab5 and not in other endosomal compart-
ments and perforin-containing cytotoxic granules (Rajagopalan
et al., 2006).
This endosomal targeting is unique to KIR2DL4 as other KIR
family members are expressed at high levels on the cell surface.
Interestingly, it is the Ig domains and not the cytoplasmic tail
of KIR2DL4 that control endosomal localization (Rajagopalan,
2010). This was shown by expression of wild-type and chimeric
KIR2DL4 receptors in HEK 293T cells and determining their
localization by confocal microscopy. A chimera consisting of the
extracellular portion of a cell surface NK receptor, gp49B, fused
to the transmembrane and tail of KIR2DL4 was not targeted to
endosomes and was expressed at the cell surface. In contrast,
the Ig domains of KIR2DL4 fused to the transmembrane and
tail of gp49B was still targeted to endosomes, showing that the
Ig domains were sufﬁcient to target the receptor to endosomes
(Rajagopalan et al., 2006).
SIGNALING FROM ENDOSOMES
Expression of wild-type and chimeric mutants of KIR2DL4 in
293T, and testing for their ability to induce IL-8 secretion proved
to be a useful screen for their signaling capability. Such analysis of
engineered mutants showed that KIR2DL4 needed to be in endo-
somes to signal, as chimeric receptors targeted to the cell surface
could not signal upon crosslinking at the cell surface. In addition,
the cytoplasmic tail of KIR2DL4 was essential for signaling and
this endosomal signaling was shown to be independent of both
ITIM- and ITAM-mediated signaling (Rajagopalan, 2010). Unlike
other KIR at the cell surface that initiate signals through src family
kinases such as fyn and lck, signaling by KIR2DL4 was resistant to
inhibitors of src family kinases and of phosphoinositide 3 kinase
(PI3K; Rajagopalan et al., 2010). Kinase phosphorylation proﬁling
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identiﬁed the phosphorylation of Akt at serine 473 in response
to signaling by KIR2DL4 and this was dependent on its endo-
cytosis (Rajagopalan et al., 2010). The link between regulators of
Akt activation and KIR2DL4 was identiﬁed by mass spectrometry
analysis of associated proteins. This approach revealedDNA-PKcs,
a DNA damage signaling kinase as the regulator of Akt. Inhibition
of DNA-PKcs blockedAkt phosphorylation, showing that Akt acts
downstream of DNA-PKcs (Rajagopalan et al., 2010). In addition,
the kinase activity of DNA-PKcs was needed for KIR2DL4 signal-
ing as shown by impaired signaling in the presence of a kinase dead
DNA-PKcs. Finally, KIR2DL4 activates a NF-κB response via the
canonical pathway to generate a proinﬂammatory/proangiogenic
response. In primary NK cells, the phosphorylation of IκBα and
the nuclear translocation of p65, both key events during NF-
κB activation, were detected in response to signaling induced
by both agonist antibody and soluble HLA-G (Rajagopalan et al.,
2010). Phosphorylation of IKKα and IKKβ was detected in an
IL-2-activated NK cell line upon antibody crosslinking of surface
KIR2DL4 (Miah et al., 2008). In contrast, theDNA-PKcs–Akt–NF-
κB signaling pathway occurs in cells that have no detectable surface
KIR2DL4. Negative regulation of KIR2DL4 signaling involves
Triad3A, an ubiquitin ligase that binds the cytoplasmic tail of
KIR2DL4 and promotes its degradation (Miah et al., 2011). Thus,
endosomal signaling by KIR2DL4 ensures sustained signals for the
secretion of numerous cytokines and chemokines such as IFN-γ,
TNF-α, IL-1α, IL-1β, IL-6, and IL-8. An advantage of such intra-
cellular signaling is that it may escape regulation by inhibitory
receptors at the NK cell surface.
EVIDENCE FOR KIR2DL4–HLA-G INTERACTIONS
The only known ligand for KIR2DL4 is the non-classical MHC
class I molecule HLA-G. The soluble form of HLA-G may be its
natural ligand as it accumulates in KIR2DL4+ endosomes and
induces endosomal signaling. Soluble HLA-G can be generated
either by shedding as a result of the metalloprotease-mediated
cleavage of the extracellular domain of the transmembrane iso-
form HLA-G1 (Park et al., 2004), or by alternative RNA splicing
to produce the soluble form known as HLA-G5. Transfected cells
expressing a high level of cell surface HLA-G1 were shown to bind
recombinant Ig-fusion proteins of KIR2DL4 (Ponte et al., 1999;
Rajagopalan and Long, 1999). This binding was blocked bymono-
clonal antibodies (mAb) to HLA-G and to KIR2DL4 (Rajagopalan
et al., 2006).
However, so far, no direct binding of soluble forms of HLA-G
to KIR2DL4 has been detected as measured by surface plasmon
resonance (Boyson et al., 2002). This could be due to an intrin-
sic low afﬁnity, as has been the case with activating forms of KIR
and their potential MHC-I ligands (Long and Rajagopalan, 2000).
Tetrameric HLA-G bound to its ligand ILT4 (CD58d/LILRB2) on
monocytic cells, but not to ILT2 (CD85j/LILRB1) or KIR2DL4
on NK cells (Allan et al., 1999). This is likely due to the very
low surface expression of ILT2 and KIR2DL4 in primary NK
cells. HLA-G can be expressed as monomers or disulphide-
linked homodimers on the NK cell surface (Apps et al., 2007).
While ILT2 binds preferentially to dimeric HLA-G (Shiroishi et al.,
2006), it is not known if KIR2DL4 favors HLA-G monomers over
dimers. The crystal structure of dimeric HLA-G and modeling of
KIR2DL4–HLA-G interactions indicate that steric constraints
would prevent KIR2DL4 from interacting with HLA-G in its
dimeric form (Clements et al., 2007). It has been reported that
NK cells produced cytokines in the presence of transfectants of
221 cells expressing the HLA-G homodimer, but not with those
expressing the HLA-G C42S mutant monomer (Li et al., 2009).
Since both monomers and dimers are present on the cell surface
of 221 cells expressing wild-type HLA-G, the issue is not resolved.
Moreover, Fab fragments of an agonist antibody to KIR2DL4
can activate NK cells indicating that a monomeric ligand can
work (Rajagopalan et al., 2006). The interesting question of how
KIR2DL4 signaling is initiated with a monomeric ligand remains
to be addressed.
Both soluble HLA-G5 and HLA-G shed from the cell surface of
transfected cells were accumulated into endosomes that contain
KIR2DL4 (Rajagopalan et al., 2006). This was detected by confo-
cal microscopy as co-localization of soluble HLA-G and KIR2DL4
in the same vesicular compartments. There was no accumula-
tion of soluble HLA-C under the same conditions. Evidence for
direct binding was obtained by showing that endocytosis of solu-
ble HLA-G was blocked in the presence of a soluble KIR2DL4-Ig
fusion protein, while a soluble KIR2DL1-Ig fusion protein did
not block uptake of soluble HLA-G (Rajagopalan, 2010). It is
likely that transient passage of KIR2DL4 at the cell surface, either
by newly synthesized KIR2DL4 or by recycling of endosomal
KIR2DL4, is sufﬁcient to capture soluble HLA-G and transport
it to endosomes.
Signaling from endosomes offers advantages that are not avail-
able to receptors that signal from the cell surface. Endosomal
signaling is sustained, lastingminutes to hours in contrast to short-
lived cell surface signals. Small endosomal volumes allow for the
maintenance of weak receptor–ligand interactions that allow sig-
naling by summation of multiple weak interactions. Endosomes
also favor signal maintenance due to slow endosomal sorting and
sequestration of signaling complexes in a small volume. Impor-
tantly, low in vivo levels of ligand can also be overcome by ligand
accumulation in endosomes over time. In this way, endosomes
provide a platform to optimize weak receptor–ligand interactions
due to either afﬁnity considerations or due to limiting amounts of
ligand (Scita and Di Fiore, 2010).
PHYSIOLOGICAL RELEVANCE OF KIR2DL4–HLA-G
INTERACTIONS
HLA-G is unusual among HLA molecules in its unique pat-
tern of expression in healthy individuals. Unlike classical MHC-I
molecules that are widely expressed onmost somatic cells, HLA-G
expression is restricted to fetal trophoblast cells at the maternal–
fetal interface. However, there is evidence of up-regulation of
HLA-GmRNA in response to transformation, neovascularization,
inﬂammation, and infection (Carosella et al., 2008). There is also
evidence for increased soluble HLA-G secretion in the serum of
patients with malignancies such as melanoma, glioma, ovarian,
and breast cancer (Rebmann et al., 2003). Increased levels of cir-
culating sHLA-G have also been detected in viral infections such as
HIV-1 (Huang et al., 2010). In the transplantation setting, induc-
tion of HLA-G expression correlates with increased transplant
acceptance. In healthy individuals, the best-documented evidence
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of HLA-G protein expression occurs on fetal trophoblast cells that
invade the maternal decidua during early pregnancy (Moffett and
Loke, 2006). Known receptors for HLA-G are found on NK cells
(KIR2DL4 and ILT2) and on monocytic cells (ILT2 and ILT4). All
these receptors are present on innate immune cells that comprise
themajority of lymphocytes at thematernal–fetal interface in early
pregnancy (Moffett-King, 2002).
The presence of soluble HLA-G in human embryo culture
supernatants after in vitro fertilization (IVF) correlates with suc-
cessful pregnancy and reduced levels of HLA-G in maternal
circulation has been reported in disorders of pregnancy, such as
pre-eclampsia and recurrent spontaneous abortion (Rizzo et al.,
2010). What is the role of HLA-G and its interactions with NK
cells in early pregnancy? The earlier view that HLA-G is tolero-
genic by protecting the fetus from attack by maternal NK cells is
losing support, as newer ﬁndings do not support the role of HLA-
G as a tolerancemolecule in this context (van derMeer et al., 2004,
2007; Li et al., 2009). In addition to HLA-G, HLA-C, and HLA-E
are present on fetal trophoblast cells. Both HLA-C and HLA-E can
block NK lysis upon recognition of combinations of inhibitory
KIR and CD94/NKG2A receptors expressed by all uterine NK cells
(Moffett-King, 2002). Moreover, much of the inhibitory function
ascribed to HLA-G is now recognized to be due to HLA-E, since
HLA-G expression in cells promotes HLA-E co-expression. This
occurs upon binding of the HLA-G signal peptides to the HLA-E
peptide-binding groove, resulting in the proper assembly and cell
surface expression of HLA-E. In this way, expression of HLA-E
on trophoblast cells allows global inhibition of NK cytotoxicity
through CD94/NKG2A. Early reports on the effects of HLA-G on
NK cells used total peripheral blood mononuclear cells (PBMC)
and not puriﬁed NK cells to assess NK cell lytic activity (Rouas-
Freiss et al., 1997a,b; Riteau et al., 2001a,b). The inhibitory effect
of HLA-G was later shown to be on T cells and not on NK cells.
Thus, while HLA-G inhibits the proliferation and cytotoxic activ-
ity of T cells, it activates decidual NK cells to secrete cytokines and
to proliferate (van der Meer et al., 2004, 2007).
In view of the ability of HLA-G to induce secretion of cytokines
and other factors by NK cells and the requirement for soluble
mediators to promote the remodeling of the maternal vascula-
ture in early pregnancy, it is likely that HLA-G interacts with
KIR2DL4 on NK cells to regulate the production of cytokines and
chemokines to promote fetal well being (Figure 2). Several genetic
association studies point to a useful role for NK activation in early
pregnancy and the presence of activatingKIR such asKIR2DS1 has
been shown to favor reproductive success (Parham and Guethlein,
2010; Chazara et al., 2011). In agreement with this, the production
of proinﬂammatory cytokines in response to HLA-G has been
detected in resting peripheral blood NK cells (Rajagopalan et al.,
2006), in uterine NK cells isolated during the window of implan-
tation (van der Meer et al., 2004, 2007) and in activated decidual
FIGURE 2 | A potential role for KIR2DL4–HLA-G interactions in early
pregnancy. NK cells are abundant in the non-pregnant endometrium
(left panel) in the secretory phase of the menstrual cycle. In early pregnancy
(right panel), interactions between fetal extravillous trophoblast cells (EVT)
and NK cells in the decidua contribute to the remodeling of the spiral
arteries to allow increased blood supply to the fetus. Fetal trophoblast
cells secrete soluble HLA-G (sG), which can be endocytosed by KIR2DL4
into endosomes. Endosomal signaling then results in a sustained
proinﬂammatory/proangiogenic secretory response that may promote
the vascular changes seen in early pregnancy.
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NK cells from ﬁrst trimester abortions (Li et al., 2009). Analysis of
the transcriptional response to activation via KIR2DL4 revealed
the up-regulation of a restricted set of chemokines and cytokines,
including IFN-γ, TNF-α, IL-1β, IL-6, and IL-8 that can promote
vascular remodeling either directly or indirectly by acting on other
cell types in the local environment (Rajagopalan et al., 2006; Miah
et al., 2008; Li et al., 2009).
CONCLUSION
KIR2DL4 is an unusual member of the KIR family of recep-
tors. It is expressed by all NK cells and by a subset of T cells.
It resides in endosomes and can signal from there through a
serine/threonine kinase cascade involving DNA-PKcs, Akt, and
NF-κB. This endosomal signaling results in sustained signals
for a proinﬂammatory/proangiogenic response. The ligand of
endosomal KIR2DL4 is soluble HLA-G. The selective expression
of HLA-G at the maternal–fetal interface, where NK cells are
abundant, implies a role for KIR2DL4 during implantation and
placentation. Since soluble HLA-G expression is also induced in
stress and disease settings, such as tumors, transplantation sites,
and during certain infections, it will be important to examine how
NK cells and T cells respond to HLA-G at these sites.
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